Analysts Reiterate Buy Rating on Palvella Therapeutics

Summary

Analysts have issued a Buy rating for Palvella Therapeutics, citing the innovative QTORIN 3.9% rapamycin gel for venous malformations and ongoing Phase 2 TOIVA trial. The stock has a consensus price target of $68.27, with Stifel Nicolaus raising its target to $80.00.Tip Ranks+ 3

Impact Analysis

So basically, analysts are very optimistic about Palvella Therapeutics right now. The key driver here is the QTORIN 3.9% rapamycin gel, which addresses significant unmet needs in venous malformations with minimal systemic absorption. The ongoing Phase 2 TOIVA trial, with results expected in December 2025, is a major catalyst. Stifel Nicolaus has raised its price target to $80.00, indicating a potential upside of 34.43% from the previous close.Tip Ranks+ 2 The company’s strong financial position, with over two years of cash runway, further supports the bullish sentiment.Tip Ranks Institutional investors are also showing confidence, with Clio Asset Management recently acquiring shares.Market Beat The market might be underestimating the potential impact of the upcoming trial results and the expansion into new indications. This feels like a solid buy, especially given the multiple buy ratings and high price targets from reputable analysts.